{"denoms":[{"counts":[{"groupId":"BG000","value":"146"},{"groupId":"BG001","value":"73"},{"groupId":"BG002","value":"219"}],"units":"Participants"}],"groups":[{"description":"5 milligram tablets administered orally in an outpatient setting according to the protocol-specified dosing schedule","id":"BG000","title":"Ruxolitinib"},{"description":"Commercially available therapy, oral or parenteral, per manufacturer's instructions and Investigator discretion. BAT included the option of no treatment.","id":"BG001","title":"Best Available Therapy (BAT)"},{"description":"Total of all reporting groups","id":"BG002","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"9.74","value":"65.1"},{"groupId":"BG001","spread":"10.27","value":"65.2"},{"groupId":"BG002","spread":"9.89","value":"65.2"}]}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Age, Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"63"},{"groupId":"BG001","value":"31"},{"groupId":"BG002","value":"94"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"83"},{"groupId":"BG001","value":"42"},{"groupId":"BG002","value":"125"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"77"},{"groupId":"BG001","value":"39"},{"groupId":"BG002","value":"116"}],"title":"Primary Myelofibrosis"},{"measurements":[{"groupId":"BG000","value":"48"},{"groupId":"BG001","value":"20"},{"groupId":"BG002","value":"68"}],"title":"Post-polycythemia vera-myelofibrosis"},{"measurements":[{"groupId":"BG000","value":"21"},{"groupId":"BG001","value":"14"},{"groupId":"BG002","value":"35"}],"title":"Post-essential thrombocythemia-myelofibrosis"}]}],"description":"Disease characteristics at baseline. Overall, (primary myelofibrosis (PMF), post-polycythemia vera-myelofibrosis(PPV-MF) and post-essential thrombocythemia-myelofibrosis (PET-MF) were diagnose in participants. The frequency of PMF was similar between ruxolitinib and BAT arms. In addition, the frequencies of PPV-MF and PET-MF were also similar between both treatment arms.","paramType":"COUNT_OF_PARTICIPANTS","title":"Disease Profile - Type of Myelofibrosis (MF)","unitOfMeasure":"Participants"}]}